Abstract

This study examines how site-specific binding to three identified neurosteroid binding sites in the α1β3 GABAA receptor (GABAAR) contributes to neurosteroid allosteric modulation. We found that the potentiating neurosteroid, allopregnanolone, but not its inhibitory 3β-epimer epi-allopregnanolone, binds to the canonical β3(+)–α1(-) intersubunit site that mediates receptor activation by neurosteroids. In contrast, both allopregnanolone and epi-allopregnanolone bind to intrasubunit sites in the β3 subunit, promoting receptor desensitization and the α1 subunit promoting effects that vary between neurosteroids. Two neurosteroid analogues with diazirine moieties replacing the 3-hydroxyl (KK148 and KK150) bind to all three sites, but do not potentiate GABAAR currents. KK148 is a desensitizing agent, whereas KK150 is devoid of allosteric activity. These compounds provide potential chemical scaffolds for neurosteroid antagonists. Collectively, these data show that differential occupancy and efficacy at three discrete neurosteroid binding sites determine whether a neurosteroid has potentiating, inhibitory, or competitive antagonist activity on GABAARs.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Yusuke Sugasawa

    Department of Anesthesiology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1607-0460
  2. Wayland WL Cheng

    Anesthesiology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9529-9820
  3. John R Bracamontes

    Anesthesiology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Zi-Wei Chen

    Anesthesiology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-8601-2210
  5. Lei Wang

    Anesthesiology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Allison L Germann

    Anesthesiology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  7. Spencer R Pierce

    Anesthesiology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Thomas C Senneff

    Anesthesiology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Kathiresan Krishnan

    Department of Developmental Biology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. David E Reichert

    Radiology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Douglas F Covey

    Department of Developmental Biology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  12. Gustav Akk

    Anesthesiology, Washington University in St Louis, St Louis, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Alex S Evers

    Anesthesiology, Washington University in St Louis, St Louis, United States
    For correspondence
    eversa@wustl.edu
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0342-0575

Funding

National Institutes of Health (2R01GM108799-05)

  • Alex S Evers

National Institutes of Health (2R01GM108799-05)

  • Douglas F Covey

National Institutes of Health (5K08GM126336-03)

  • Wayland WL Cheng

National Institutes of Health (5R01GM108580-06)

  • Gustav Akk

Taylor Family Institute for Innovative Psychiatric Research

  • Alex S Evers

Taylor Family Institute for Innovative Psychiatric Research

  • Gustav Akk

Taylor Family Institute for Innovative Psychiatric Research

  • Douglas F Covey

Taylor Family Institute for Innovative Psychiatric Research

  • David E Reichert

Taylor Family Institute for Innovative Psychiatric Research

  • Zi-Wei Chen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2020, Sugasawa et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,120
    views
  • 450
    downloads
  • 39
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yusuke Sugasawa
  2. Wayland WL Cheng
  3. John R Bracamontes
  4. Zi-Wei Chen
  5. Lei Wang
  6. Allison L Germann
  7. Spencer R Pierce
  8. Thomas C Senneff
  9. Kathiresan Krishnan
  10. David E Reichert
  11. Douglas F Covey
  12. Gustav Akk
  13. Alex S Evers
(2020)
Site-specific effects of neurosteroids on GABAA receptor activation and desensitization
eLife 9:e55331.
https://doi.org/10.7554/eLife.55331

Share this article

https://doi.org/10.7554/eLife.55331

Further reading

    1. Developmental Biology
    2. Structural Biology and Molecular Biophysics
    Elise S Bruguera, Jacob P Mahoney, William I Weis
    Research Article

    Wnt/β-catenin signaling directs animal development and tissue renewal in a tightly controlled, cell- and tissue-specific manner. In the mammalian central nervous system, the atypical ligand Norrin controls angiogenesis and maintenance of the blood-brain barrier and blood-retina barrier through the Wnt/β-catenin pathway. Like Wnt, Norrin activates signaling by binding and heterodimerizing the receptors Frizzled (Fzd) and low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6), leading to membrane recruitment of the intracellular transducer Dishevelled (Dvl) and ultimately stabilizing the transcriptional coactivator β-catenin. Unlike Wnt, the cystine knot ligand Norrin only signals through Fzd4 and additionally requires the co-receptor Tetraspanin12 (Tspan12); however, the mechanism underlying Tspan12-mediated signal enhancement is unclear. It has been proposed that Tspan12 integrates into the Norrin-Fzd4 complex to enhance Norrin-Fzd4 affinity or otherwise allosterically modulate Fzd4 signaling. Here, we measure direct, high-affinity binding between purified Norrin and Tspan12 in a lipid environment and use AlphaFold models to interrogate this interaction interface. We find that Tspan12 and Fzd4 can simultaneously bind Norrin and that a pre-formed Tspan12/Fzd4 heterodimer, as well as cells co-expressing Tspan12 and Fzd4, more efficiently capture low concentrations of Norrin than Fzd4 alone. We also show that Tspan12 competes with both heparan sulfate proteoglycans and LRP6 for Norrin binding and that Tspan12 does not impact Fzd4-Dvl affinity in the presence or absence of Norrin. Our findings suggest that Tspan12 does not allosterically enhance Fzd4 binding to Norrin or Dvl, but instead functions to directly capture Norrin upstream of signaling.

    1. Structural Biology and Molecular Biophysics
    Laura-Marie Silbermann, Benjamin Vermeer ... Katarzyna Tych
    Review Article

    Molecular chaperones are vital proteins that maintain protein homeostasis by assisting in protein folding, activation, degradation, and stress protection. Among them, heat-shock protein 90 (Hsp90) stands out as an essential proteostasis hub in eukaryotes, chaperoning hundreds of ‘clients’ (substrates). After decades of research, several ‘known unknowns’ about the molecular function of Hsp90 remain unanswered, hampering rational drug design for the treatment of cancers, neurodegenerative, and other diseases. We highlight three fundamental open questions, reviewing the current state of the field for each, and discuss new opportunities, including single-molecule technologies, to answer the known unknowns of the Hsp90 chaperone.